Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Optimising invasive aspergillosis treatment in the current environment 

This promotional meeting is organised and funded by Pfizer and may include reference to Pfizer medicines relevant to agenda topics.

  • Fungal Topic

Optimising invasive aspergillosis treatment in the current environment

Date: 24th November & 26th November

Time: 12pm - 24th November 
            6pm - 26th November

Duration: 1 Hour

Additional details: This is a live webinar. A live Q&A with Dr Andy Peniket will be available. 

Register Here

About the webinar

This webinar is a promotional meeting that  will focus on:
•    Sharing experience on how to optimise treatment of invasive aspergillosis and minimise patients' hospital stay
•    How to complete the Blueteq form
•    The cost-effectiveness model of Cresemba (isavuconazole)

About the speaker

Dr Andy Peniket
Clinical Director of Haematology and Bone Marrow Transplant, 
Oxford University Hospitals Trust

Intended audience

HCPs working in the following specialities: Microbiologists, Infectious diseases, Haematology, Intensive Care, Respiratory, Transplant surgery, Hospital pharmacists, Hospital nurses

This meeting is organised & funded by Pfizer Ltd. Please note that, under the law and the ABPI Code of Practice, Pfizer may only promote its medicines and provide hospitality to members of the healthcare professions and other relevant decision makers. Therefore, no unqualified person (e.g. medical students, non-medical spouses/partners/family members) may be invited to or attend Pfizer promotional meetings.

 

Prescribing information 

Cresemba(isavuconazole)
Cresemba 100mg hard capsules – SPC
Legal Category: POM. Basic NHS Cost:14 caps pack £599.28
Cresemba 200mg powder for concentrate for solution for infusion – SPC
Legal Category: POM. Basic NHS Cost: 1 vial pack £297.84